Dr. Sager is an Adjunct Professor of Medicine at the Stanford University School of Medicine, the previous chair of the FDA Cardiovascular and Renal Drugs Advisory Committee, and an Executive Committee member of the FDA-Sponsored Cardiac Safety Research Consortium. He has played a major leadership role in CV safety issues in drug development. Dr. Sager was the ICH E14 (“the QT Guidance”) PhARMA Expert Working Group Topic Leader and is a Steering Committee Member of the FDA Comprehensive In Vitro Proarrhythmia Assay (CIPA) effort. He is a member of the Board of Directors of Anthera, Inc. Previous roles have included a tenured faculty appointment at the UCLA School of Medicine, senior leadership roles in the pharmaceutical industry, including Vice President, CV/Metabolic Development at Gilead Sciences and Executive Director at AstraZeneca. Dr. Sager has major development leadership on multiple drugs including Zetia®, Vytorin®, Crestor®, Ranexa®, Letairis®, and Brilinta. He holds an M.D. from Yale University School of Medicine, B.S. degrees in biology and chemistry from the Massachusetts Institute of Technology, trained in internal medicine and cardiology at the Yale School of Medicine, and has published more than 200 original manuscripts and abstracts.